JPMorgan Chase Discloses 5.0% Stake in Amicus Therapeutics

TL;DR

**JPMorgan Chase just revealed a 5% stake in Amicus Therapeutics, signaling institutional interest.**

AI Summary

JPMorgan Chase & Co. reported on January 8, 2024, that as of December 29, 2023, they beneficially own 5.0% of Amicus Therapeutics, Inc.'s common stock. This filing indicates that JPMorgan Chase & Co. holds a significant, but not controlling, stake in Amicus Therapeutics, a pharmaceutical company. For investors, this means a major financial institution sees value in Amicus, potentially signaling confidence, but it doesn't imply any immediate strategic changes or a takeover.

Why It Matters

This filing shows a large institutional investor, JPMorgan Chase & Co., has taken a notable position in Amicus Therapeutics, which can be seen as a vote of confidence in the company's future.

Risk Assessment

Risk Level: low — This filing indicates a passive investment by a large institution, which generally reduces risk by adding stability and institutional backing.

Analyst Insight

A smart investor would view this as a positive signal, suggesting institutional confidence in Amicus Therapeutics, and might consider further research into the company's fundamentals.

Key Numbers

• 5.0% — Beneficial Ownership (The percentage of Amicus Therapeutics' common stock owned by JPMorgan Chase & Co. as of December 29, 2023.)
• 03152W109 — CUSIP Number (The unique identification number for Amicus Therapeutics' common stock.)

Key Players & Entities

• JPMorgan Chase & Co. (company) — the entity filing the SC 13G, reporting beneficial ownership
• Amicus Therapeutics, Inc. (company) — the subject company whose securities are being reported
• 5.0% (dollar_amount) — the percentage of Amicus Therapeutics' common stock beneficially owned by JPMorgan Chase & Co.
• December 29, 2023 (person) — the date of the event requiring the filing of this statement
• $0.01 (dollar_amount) — the par value per share of Amicus Therapeutics' common stock

Forward-Looking Statements

• Amicus Therapeutics will likely see increased institutional investor interest following JPMorgan's disclosure. (Amicus Therapeutics, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.01 — ame of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securiti

Filing Documents

• Amicus_Therapeutics_Inc.ht.htm (SC 13G) — 86KB
• 0000019617-24-000026.txt ( ) — 88KB

From the Filing

SC 13G 1 Amicus_Therapeutics_Inc.ht.htm FILING AMICUS THERAPEUTICS, INC. Schedule 13G UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Amicus Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 03152W109 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Rule 13d-1(b) o Rule 13d-1(c) o Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 03152W109 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) JPMORGAN CHASE & CO. 13-2624428 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) o (b) o 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 15,895,043 6 SHARED VOTING POWER 0 7 SOLE DISPOSITIVE POWER 17,481,616 8 SHARED DISPOSITIVE POWER 1,164 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 17,502,680 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.9 % 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC FOOTNOTES Item 1. (a) Name of Issuer Amicus Therapeutics, Inc. (b) Address of Issuer's Principal Executive Offices 47 Hulfish Street, Princeton, NJ 08542 Item 2. (a) Name of Person Filing JPMORGAN CHASE & CO. (b) Address of Principal Business Office or, if none, Residence 383 Madison Avenue New York, NY 10179 (c) Citizenship Delaware (d) Title of Class of Securities Common Stock, par value $0.01 per share (e) CUSIP Number 03152W109 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) o An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) o An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) x A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) o A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J). (k) o A group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 17,502,680 (b) Percent of class: 5.9 % (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 15,895,043 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 17,481,616 (iv) Shared power to dispose or to direct the disposition of: 1,164 Item 5. of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o . Item 6. of More than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company J.P. Morgan Trust Company of Delaware J.P. Morgan Securities LLC JPMorgan Chase Bank, National Association J.P. Morgan Inves

View Full Filing

View this SC 13G filing on SEC EDGAR